Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance

The Pediatric Infectious Disease Journal 2026

View at publisher
Authors: Hardik Chandasana, Ann M. Buchanan, Cassidy Henegar, Michael McKenna, Cindy Vavro, Ana Puga, Cindy H Brothers, Lionel Tan, Mark Bush, Rashmi Mehta, Mary Paul, Linda Lewis
+1 more Theodore Ruel
DOI: 10.1097/inf.0000000000005158
Cited by: 0
References: 8

Abstract

Twice-daily dosing of Dolutegravir is approved for adults with HIV and integrase strand transfer inhibitor resistance, but not for children. Population pharmacokinetic modeling and simulations identified a weight-tiered twice-daily dose for children, predicted to yield dolutegravir exposures within the therapeutic window and provide similar efficacy and safety as seen in adults with HIV-1 and first-generation integrase strand transfer inhibitor resistance.

Fields of Study & Subjects

HIV/AIDS drug development and treatment Pharmaceutical studies and practices HIV/AIDS Research and Interventions

Publication details

Journal / source
The Pediatric Infectious Disease Journal
Volume
45
Issue
7
Pages
620–622
Publication date
4 February 2026
Language
EN